Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE versus CLINDAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE versus CLINDAMYCIN.
CLEOCIN PHOSPHATE vs Clindamycin
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin. Clindamycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. It exhibits bacteriostatic activity against susceptible bacteria.
Inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
600-2700 mg/day IV/IM in 2-4 divided doses. Typical: 600-900 mg IV q8h or 300-600 mg IM q12h.
150-450 mg orally every 6 hours; 600 mg to 1.2 g intravenously every 6-8 hours; maximum 4.8 g/day IV.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in adults with normal renal and hepatic function; may be prolonged to 4-5 hours in patients with severe hepatic impairment (Child-Pugh C). In neonates, half-life ranges from 8-12 hours, decreasing to adult values by 1 month of age.
Clinical Note
moderateClindamycin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Clindamycin."
Clinical Note
moderateClindamycin + Clotrimazole
2.4 hours (range 1.5-5.1 hours) in adults with normal renal function; prolonged in severe hepatic impairment.
Approximately 10% as active drug and metabolites in urine, 3.6% in feces; major route is hepatic metabolism to inactive metabolites (N-demethylclindamycin and clindamycin sulfoxide) excreted in bile and feces. Renal excretion accounts for about 10% of the dose, with the remainder eliminated via biliary/fecal route.
Approximately 10% of active drug and 90% as inactive metabolites via renal (feces 3.6% as active, bile significant for enterohepatic circulation).
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic
"The metabolism of Clotrimazole can be decreased when combined with Clindamycin."